{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["106(5)"],"submitter":["Jachiet V"],"pubmed_abstract":["Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessing this association are missing. Whether such patients have a particular phenotype and require particular management is unclear. This study analyzes the clinical spectrum, outcome and therapeutic management of patients with ITP associated with MDS or CMML, in comparison (i) to patients with primary ITP without MDS/CMML and (ii) to patients with MDS/CMML without ITP. Forty-one MDS/CMML-associated ITP patients were included, with chronic ITP in 26 (63%) patients, low-risk myelodysplasia in 30 (73%) patients and CMML in 24 (59%) patients. An associate"],"journal":["Haematologica"],"pagination":["1414-1422"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8094121"],"repository":["biostudies-literature"],"pubmed_title":["Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia."],"pmcid":["PMC8094121"],"pubmed_authors":["Jachiet V","Sacre K","Ades L","Fenaux P","Mekinian A","Vey N","Salvado C","Versini M","Fain O","Gaudin C","Bouvet R","Beyne-Rauzy O","Broner J","Seguier J","Peterlin P","Brun N","Laribi K","Lambotte O","Roy-Peaud F","Schleinitz N","Moulis G","Hadjadj J","Isnard F","Godeau B","Gobert D","Comont T","Kahn JE","Le Clech L"],"additional_accession":[]},"is_claimable":false,"name":"Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.","description":"Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessing this association are missing. Whether such patients have a particular phenotype and require particular management is unclear. This study analyzes the clinical spectrum, outcome and therapeutic management of patients with ITP associated with MDS or CMML, in comparison (i) to patients with primary ITP without MDS/CMML and (ii) to patients with MDS/CMML without ITP. Forty-one MDS/CMML-associated ITP patients were included, with chronic ITP in 26 (63%) patients, low-risk myelodysplasia in 30 (73%) patients and CMML in 24 (59%) patients. An associate","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2026-06-20T04:45:49.18Z","creation":"2026-06-20T03:10:14.777Z"},"accession":"S-EPMC8094121","cross_references":{"pubmed":["33626866"],"doi":["10.3324/haematol.2020.272559"]}}